Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis

Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis

Objectives To compare the cost-effectiveness of tildrakizumab with other commonly used biologics and apremilast as the first-line treatment for moderate-to-severe plaque psoriasis from a US health plan’s perspective. Methods A 10-year cost-effectiveness model was developed to compare the incremental...

Full description

Bibliographic Details
Main Authors: Jashin J. Wu, Xiaoying Jia, Yang Zhao, Justin Carrico, Thor-Henrik Brodtkorb, Alan Mendelsohn, Simon Lowry, Steven R. Feldman, April Armstrong
Format: Article
Language:English
Published: Taylor & Francis Group 2021-10-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
cost effectiveness
biologic therapy
apremilast
Online Access:http://dx.doi.org/10.1080/09546634.2019.1698700

Internet

http://dx.doi.org/10.1080/09546634.2019.1698700

Similar Items